長江健康(002435.SZ):注射用頭孢唑林鈉通過一致性評價
格隆匯1月21日丨長江健康(002435.SZ)公佈,公司今日收到下屬全資子公司海南海靈化學制藥有限公司(以下簡稱“海靈藥業”)的通知,海靈藥業收到國家藥品監督管理局核准簽發的注射用頭孢唑林鈉《藥品補充申請批准通知書》,批准該藥品通過仿製藥質量和療效一致性評價(以下簡稱“一致性評價”)。
頭孢唑林鈉是第一代頭孢菌素,抗菌譜廣,適用於治療敏感細菌所致的呼吸道感染、尿路感染、皮膚軟組織感染、骨和關節感染、敗血症、感染性心內膜炎、肝膽系統感染、生殖系統感染、圍手術期預防感染。
注射用頭孢唑林鈉對葡萄球菌包括產β內酰胺黴菌株、鏈球菌、大腸桿菌和奇異變形桿菌引起的感染有效,臨牀上廣泛用於預防手術感染,尤其是預防膽道手術、整形外科、心臟和婦科外科手術感染。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.